title: Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.
abstract: Parathyroid hormone (PTH) is the only approved anabolic agent for osteoporosis treatment. It acts via osteoblasts to stimulate both osteoclast formation and bone formation, with the balance between these two activities determined by the mode of administration. Oncostatin M (OSM), a gp130-dependent cytokine expressed by osteoblast lineage cells, has similar effects and similar gene targets in the osteoblast lineage. In this study, we investigated whether OSM might participate in anabolic effects of PTH. Microarray analysis and quantitative real-time polymerase chain reaction (qPCR) of PTH-treated murine stromal cells and primary calvarial osteoblasts identified significant regulation of gp130 and gp130-dependent coreceptors and ligands, including a significant increase in OSM receptor (OSMR) expression. To determine whether OSMR signaling is required for PTH anabolic action, 6-week-old male Osmr(-/-) mice and wild-type (WT) littermates were treated with hPTH(1-34) for 3 weeks. In WT mice, PTH increased trabecular bone volume and trabecular thickness. In contrast, the same treatment had a catabolic effect in Osmr(-/-) mice, reducing both trabecular bone volume and trabecular number. This was not explained by any alteration in the increased osteoblast formation and mineral apposition rate in response to PTH in Osmr(-/-) compared with WT mice. Rather, PTH treatment doubled osteoclast surface in Osmr(-/-) mice, an effect not observed in WT mice. Consistent with this finding, when osteoclast precursors were cultured in the presence of osteoblasts, more osteoclasts were formed in response to PTH when Osmr(-/-) osteoblasts were used. Neither PTH1R mRNA levels nor cAMP response to PTH were modified in Osmr(-/-) osteoblasts. However, RANKL induction in PTH-treated Osmr(-/-) osteoblasts was sustained at least until 24 hours after PTH exposure, an effect not observed in WT osteoblasts. These data indicate that the transient RANKL induction by intermittent PTH administration, which is associated with its anabolic action, is changed to a prolonged induction in OSMR-deficient osteoblasts, resulting in bone destruction.
authors.affiliation: St. Vincent's Institute of Medical Research, Melbourne, Victoria, Australia.
authors.forename: Emma C
authors.initials: EC
authors.lastname: Walker
authors.forename: Ingrid J
authors.initials: IJ
authors.lastname: Poulton
authors.forename: Narelle E
authors.initials: NE
authors.lastname: McGregor
authors.forename: Patricia W M
authors.initials: PW
authors.lastname: Ho
authors.forename: Elizabeth H
authors.initials: EH
authors.lastname: Allan
authors.forename: Julie M
authors.initials: JM
authors.lastname: Quach
authors.forename: T John
authors.initials: TJ
authors.lastname: Martin
authors.forename: Natalie A
authors.initials: NA
authors.lastname: Sims
mesh_terms: D045930:Anabolic Agents / Q000494:pharmacology*; D000818:Animals; D002460:Cell Line; D050822:Cytokine Receptor gp130 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008297:Male; D051379:Mice; D020411:Oligonucleotide Array Sequence Analysis; D009929:Organ Size / Q000187:drug effects; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism*; D010281:Parathyroid Hormone / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D053245:RANK Ligand / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D053677:Receptors, Oncostatin M / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism
chemical_list: D045930:Anabolic Agents; D016207:Cytokines; D010281:Parathyroid Hormone; D053245:RANK Ligand; D012333:RNA, Messenger; D053677:Receptors, Oncostatin M; D050822:Cytokine Receptor gp130